A lung cancer drug already available on the NHS has been proven to cut bladder cancer deaths and reduce the risk of the ...
The counterfeit versions of the cancer immunotherapy Imfinzi have been found in Armenia, Lebanon, and Türkiye.
AstraZeneca's Calquence gains FDA approval for untreated mantle cell lymphoma, supported by data showing improved survival and reduced disease progression.
The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...
Durvalumab (brand name Imfinzi) is a treatment for non small cell lung cancer (NSCLC) but is also being trialled in other cancers. James Catto, professor of urology at the University of Sheffield ...
The Independent on MSN6d
‘Game changer’ immunotherapy drug could lead to increased survival rates for bladder cancer patientsThe study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...
Immunotherapy drug durvalumab, sold under the brand name Imfinzi, could help reduce the risk of bladder cancer progressing or returning to patients, according to a new study. Patients were given ...
As 2025 begins, we would like to reflect on last year’s regulatory developments in the biologics and biosimilars space. Here are ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback